Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Keros Therapeutics (KROS) Net Income towards Common Stockholders (2019 - 2025)

Historic Net Income towards Common Stockholders for Keros Therapeutics (KROS) over the last 7 years, with Q3 2025 value amounting to -$7.3 million.

  • Keros Therapeutics' Net Income towards Common Stockholders rose 8625.27% to -$7.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $64.4 million, marking a year-over-year increase of 13549.54%. This contributed to the annual value of -$187.4 million for FY2024, which is 2245.93% down from last year.
  • Keros Therapeutics' Net Income towards Common Stockholders amounted to -$7.3 million in Q3 2025, which was up 8625.27% from -$30.7 million recorded in Q2 2025.
  • Keros Therapeutics' 5-year Net Income towards Common Stockholders high stood at $148.5 million for Q1 2025, and its period low was -$53.0 million during Q3 2024.
  • Its 5-year average for Net Income towards Common Stockholders is -$20.7 million, with a median of -$29.7 million in 2022.
  • Its Net Income towards Common Stockholders has fluctuated over the past 5 years, first tumbled by 32821.33% in 2022, then skyrocketed by 44432.2% in 2025.
  • Keros Therapeutics' Net Income towards Common Stockholders (Quarter) stood at -$6.9 million in 2021, then plummeted by 328.21% to -$29.7 million in 2022, then plummeted by 35.42% to -$40.2 million in 2023, then dropped by 14.37% to -$46.0 million in 2024, then soared by 84.18% to -$7.3 million in 2025.
  • Its last three reported values are -$7.3 million in Q3 2025, -$30.7 million for Q2 2025, and $148.5 million during Q1 2025.